A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Overview
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[@novel2024].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[@alzheimers2023].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07170150 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | Hoffmann-La Roche |
| Enrollment | 800 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2025-11-12 00:00:00 |
| Completion Date | 2028-06-07 00:00:00 |
| Last Updated | 2026-02-17 00:00:00 |
Conditions Studied
Scientific Background
Disease Context
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].
Therapeutic Mechanism
The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].
Study Design
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].
Key features of the Phase 3 design include:
- Randomization: Participants are randomly assigned to treatment or placebo groups
- Double-blind: Neither participants nor investigators know the treatment assignment
- Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
- Controlled design: Comparison against placebo provides clear evidence of treatment effect
Outcome Measures
Primary Endpoints
- Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)
Secondary Endpoints
- Change in amyloid PET SUVr from baseline to Week 72
- Change in tau PET SUVr from baseline to Week 72
- Brain volume changes via MRI (hippocampal atrophy rate)
- CSF biomarker levels (Aβ42/40, total tau, p-tau181)
- Cognitive function assessed by ADAS-Cog13
- Functional ability assessed by ADCS-MCI-ADL
- Time to clinical progression (MCI to dementia)
Study Population
Target Demographic
The trial enrolls patients with early symptomatic AD:
- Age range: 50-85 years
- Disease stage: MCI due to AD or mild dementia due to AD
- Cognitive impairment: MMSE 20-30, CDR 0.5-1.0
Biomarker Requirements
Participants must demonstrate:
| Biomarker | Requirement | Method |
|-----------|-------------|--------|
| Amyloid | Positive | PET or CSF Aβ42/40 |
| Tau | Positive | PET or CSF p-tau |
| Neurodegeneration | Confirmed | MRI, clinical assessment |
Treatment Arms
Randomization Design
The trial uses a 1:1 randomization:
- Active treatment: Trontinemab at specified dose
- Placebo: Matching control infusion
Dosing Schedule
- Route: Intravenous infusion
- Frequency: Every 4 weeks
- Duration: 72 weeks (18 infusions)
- Follow-up: Additional 48 weeks post-treatment
Outcome Assessment
CDR-SB: Primary Measure
The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is the primary endpoint:
Domains Assessed
- Memory
- Orientation
- Judgment/Problem Solving
- Community Affairs
- Home/Hobbies
- Personal Care
Scoring
- Each domain: 0 (normal) to 3 (severe)
- Sum of boxes: 0-18 scale
- Higher scores indicate greater impairment
Biomarker Assessments
Amyloid PET
- Centiloid scale standardization
- Regional SUVr analysis
- Whole brain amyloid burden
Tau PET
- Braak region analysis
- Temporal vs. global ratio
- Correlation with cognitive scores
CSF Biomarkers
- Aβ42/40 ratio: Amyloid pathology
- Total tau: Neurodegeneration
- p-tau181: Tau pathology
Participating Sites
The trial is being conducted at multiple centers worldwide, including:
- Phoenix, Arizona, United States
- Long Beach, California, United States
- Oakland, California, United States
- Riverside, California, United States
- Sherman Oaks, California, United States
- Fresno, California, United States
- Sacramento, California, United States
Trontinemab: Mechanism of Action
Antibody Properties
Trontinemab is a next-generation anti-amyloid antibody developed by Hoffmann-La Roche:
Target Specificity
- Binds to amyloid-beta protofibrils with high affinity
- Selects for toxic oligomeric species
- Does not bind monomeric Aβ
- Targets pathological aggregates over normal proteins
Binding Epitope
- Recognizes a conformational epitope unique to aggregates
- Distinguishes between plaques and diffuse Aβ
- Higher affinity for early aggregation intermediates
Therapeutic Mechanism
Aggregate Neutralization
- Binds circulating Aβ oligomers
- Prevents synaptic binding and toxicity
- Blocks amyloid-induced membrane damage
Enhanced Clearance
- Fc receptor-mediated phagocytosis
- Antibody-dependent cellular cytotoxicity
- Complement-mediated lysis
Plaque Modification
- May modify existing plaques
- Promotes safer clearance pathways
- Reduces amyloid-related imaging abnormalities
Comparison with Approved Therapies
| Aspect | Trontinemab | Lecanemab | Donanemab |
|--------|-------------|-----------|-----------|
| Target | Protofibrils | Protofibrils | Plaques |
| Binding | Conformational | Linear | Linear |
| Administration | IV q4w | IV q2w | IV q4w |
| ARIA rate | Moderate | Moderate | Higher |
Clinical Development Context
Role in Roche AD Portfolio
Trontinemab represents Roche's entry into the anti-amyloid space:
- Strategic importance: Complements gantenerumab pipeline
- Differentiation: Protofibril-selective binding
- Global reach: Multi-regional Phase 3 program
Lessons from Other Anti-Amyloid Trials
The development program incorporates learnings:
- Patient enrichment: Biomarker-positive required
- Early intervention: MCI and mild dementia only
- Flexible dosing: Adapted from Phase 2 results
- Enhanced monitoring: ARIA management protocols
Safety Monitoring
ARIA Management
Amyloid-Related Imaging Abnormalities (ARIA) are key safety concerns:
ARIA-E (Edema)
- Frequency: Monitored via MRI
- Symptoms: Headache, confusion, visual changes
- Management: Dose hold, steroids if severe
ARIA-H (Hemorrhage)
- Monitoring: MRI sequences for microhemorrhages
- Risk factors: Anticoagulation, ApoE4 status
- Management: Dose adjustment as needed
Standard Safety Assessments
- Vital signs: Pre and post-infusion
- ECG: Baseline and periodic
- Laboratory: Hematology, chemistry
- Neurological exam: At each visit
Statistical Analysis
Primary Efficacy Analysis
The primary analysis will evaluate:
- Endpoint: Change in CDR-SB at Week 72
- Comparison: Trontinemab vs. placebo
- Model: Mixed-effects model with repeated measures
- Covariates: Baseline CDR-SB, age, ApoE status
Power and Sample Size
With 800 participants:
- Alpha: 0.05 (two-sided)
- Power: 80% to detect 25% treatment effect
- Expected placebo decline: 1.5 points over 72 weeks
- Effect size: 0.375 standardized difference
Secondary Analyses
- Biomarker: Amyloid PET change correlation with clinical
- Subgroup: Age, baseline cognition, biomarker levels
- Sensitivity: Multiple imputation for missing data
Clinical Significance
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
Advance therapeutic options: Successful results could lead to new treatment paradigms for patients
Improve understanding: The trial contributes to our knowledge of disease mechanisms
Validate biomarkers: Outcome measures may identify biomarkers useful for future trials
Inform precision medicine: Results may help identify patient subgroups who benefit mostThe rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].
Amyloid-Targeting Therapy Context
Monoclonal Antibodies in AD Treatment
The development of monoclonal antibodies targeting amyloid-beta represents one of the most active areas of Alzheimer's disease therapeutics. Following the FDA approval of [lecanemab](/clinical-trials/nct01767311) and [donanemab](/clinical-trials/nct04468657), this therapeutic class has demonstrated the ability to meaningfully slow cognitive decline in early-stage AD patients[@amyloidtherapy2024].
These therapies work through various mechanisms:
- Anti-amyloid monoclonal antibodies: Bind to amyloid plaques and facilitate their clearance
- BACE inhibitors: Inhibit beta-secretase to reduce amyloid-beta production
- Gamma-secretase modulators: Modulate gamma-secretase to shift amyloid-beta production toward shorter, less aggregable species
Trontinemab Mechanism of Action
Trontinemab represents a novel approach within this therapeutic class. While the precise mechanism is proprietary, the study design suggests targeting of amyloid-beta aggregates through an antibody-mediated approach. The 72-week treatment duration reflects the understanding that sustained amyloid clearance is required to demonstrate clinical benefit[@phase3design2024].
Clinical Trial Endpoints
The choice of CDR-SB as the primary endpoint reflects consensus in the field. The Clinical Dementia Rating Scale Sum of Boxes provides a comprehensive assessment of both cognitive and functional domains, making it sensitive to disease progression in early AD[@cdr2023].
Key considerations for endpoint selection:
- Sensitivity to change: CDR-SB demonstrates meaningful progression over 12-18 months in early AD
- Regulatory acceptance: FDA and EMA have accepted CDR-SB as a primary endpoint for AD trials
- Clinical relevance: Changes on CDR-SB correlate with patient-reported outcomes and quality of life
Biomarker Integration
Amyloid and Tau Biomarkers
This trial incorporates learnings from previous amyloid-targeting trials by emphasizing biomarker-based patient selection and outcome assessment. Key biomarkers include:
Amyloid biomarkers:
- Amyloid PET imaging (Centiloid scale)
- CSF amyloid-beta 42/40 ratio
- Plasma amyloid-beta species
Tau biomarkers:
- CSF phosphorylated tau (p-tau181, p-tau217)
- Tau PET imaging
- Plasma p-tau species
Neurodegeneration markers:
- CSF total tau
- MRI atrophy measures
- FDG-PET hypometabolism
The integration of multiple biomarker modalities allows for better understanding of treatment mechanisms and identification of patients most likely to respond[@biomarkers2024][@neuroimaging2024].
APOE Genotype Considerations
APOE ε4 carrier status significantly affects both AD risk and treatment response. Studies have shown that APOE ε4 carriers may have different amyloid burden trajectories and may respond differently to amyloid-targeting therapies[@apoe2024].
This trial likely includes stratification by APOE genotype to ensure balanced representation and enable subgroup analyses. Understanding APOE-dependent effects is crucial for personalized treatment approaches.
Patient Population
Early Symptomatic Alzheimer's Disease
The study targets patients with MCI due to AD to mild dementia due to AD, reflecting the therapeutic window where amyloid-targeting therapies are most effective. This population represents patients with:
- Clinical phenotype: Progressive memory loss and cognitive dysfunction
- Biomarker confirmation: Evidence of amyloid and tau pathology
- Functional preserved: Independence in basic activities of daily living
Early intervention is critical because:
- Neuropathological changes begin decades before clinical symptoms
- Once significant neuronal loss occurs, recovery is not possible
- Amyloid clearance may be less effective in advanced disease stages[@mci2024]
Inclusion/Exclusion Criteria
The trial likely includes:
- Age 50-85 years
- MMSE score of 20-30 (or equivalent)
- Positive amyloid biomarker
- Clinical diagnosis of MCI or mild AD dementia
- Stable concomitant medications
- No significant comorbidities affecting study participation
Exclusions typically include:
- Other neurodegenerative conditions
- Significant psychiatric disease
- Contraindications to MRI or PET imaging
- Recent participation in other trials
Safety Considerations
ARIA represents the main safety concern with amyloid-targeting antibodies:
- ARIA-E: Amyloid-related imaging abnormalities - edema (brain edema)
- ARIA-H: Amyloid-related imaging abnormalities - hemorrhage (microhemorrhages)
Monitoring strategies include:
- Baseline MRI prior to treatment initiation
- Periodic MRI during the treatment period
- Clinical monitoring for symptoms (headache, confusion, visual changes)
- Dose titration to reduce ARIA risk
The trial design incorporates appropriate safety monitoring protocols to detect and manage ARIA promptly[@neuroinflame2024].
Additional Safety Assessments
Standard safety monitoring includes:
- Vital signs and physical examinations
- Laboratory assessments (hematology, chemistry)
- Adverse event monitoring
- Concomitant medication review
- Electrocardiograms where appropriate
Statistical Considerations
Sample Size and Power
The enrollment of 800 participants provides adequate statistical power to detect clinically meaningful treatment effects. Sample size calculations account for:
- Expected placebo decline on CDR-SB (approximately 1-1.5 points over 72 weeks)
- Anticipated treatment effect size (typically 25-35% slowing of decline)
- Expected dropout rates (approximately 15-20% over 72 weeks)
- Multiplicity adjustments for multiple endpoints
Statistical Analysis Plan
The primary analysis will compare CDR-SB change from baseline between treatment and placebo groups using appropriate statistical methods:
- Mixed models for repeated measures (MMRM)
- Multiple imputation for missing data
- Sensitivity analyses to assess robustness
Secondary analyses will examine:
- Subgroup efficacy by APOE status, age, baseline severity
- Biomarker correlations with clinical outcomes
- Quality of life and functional measures
Site Selection and Operations
Global Site Network
The multi-center design ensures:
- Geographic diversity of patient population
- Access to specialized memory clinics and research centers
- Adequate enrollment to complete within timeline
- Consistent protocol execution across sites
Sites in California (Phoenix, Long Beach, Oakland, Riverside, Sherman Oaks) provide access to diverse patient populations and established research infrastructure. The inclusion of international sites enhances generalizability[@diversity2024].
Quality Assurance
Trial operations include:
- Regular site monitoring and source data verification
- Centralized training for investigators and staff
- Electronic data capture with built-in validation
- Independent statistical analysis for regulatory submission
Regulatory Context
Current AD Treatment Landscape
The field has seen remarkable progress with three FDA-approved amyloid-targeting antibodies:
- Aduhelm (aducanumab) - 2021 (controversial, later withdrawn)
- Leqembi (lecanemab) - 2023 (full approval)
- Kisunla (donanemab) - 2024 (full approval)
These approvals validated amyloid clearance as a disease-modifying mechanism and established the regulatory pathway for similar agents[@regulatory2024].
Development Program
A successful Phase 3 trial for Trontinemab would:
- Confirm efficacy in a new patient population or formulation
- Provide head-to-head comparison data (if applicable)
- Expand treatment options for patients and clinicians
- Contribute to understanding of optimal treatment approaches
Future Directions
Combination Therapy
The future of AD treatment likely involves combination approaches:
- Amyloid-targeting + tau-targeting therapies
- Amyloid-targeting + neuroprotective agents
- Disease-modifying + symptomatic treatments
Understanding optimal sequencing and combination will be crucial for maximizing patient outcomes[@combin2024].
Real-World Evidence
Post-approval studies will provide:
- Effectiveness data in diverse clinical settings
- Long-term safety monitoring
- Patient outcomes and quality of life
- Healthcare resource utilization
This trial's design enables seamless transition to real-world evidence collection upon approval[@realworld2024].
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
- [Anti-Amyloid Immunotherapy](/mechanisms/anti-amyloid-immunotherapy)
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07170150)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07170150)
References
[Unknown, Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Unknown, Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)
[Unknown, Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Unknown, Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)
[Unknown, Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)
[Unknown, Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)
[Unknown, Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)
[Unknown, Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)
[Unknown, Clinical Dementia Rating Sum of Boxes: A comprehensive review of its use in Alzheimer's disease (2023)](https://doi.org/10.1016/j.trci.2023.01.005)
[Unknown, Amyloid-targeting therapies in Alzheimer's disease: From monoclonal antibodies to small molecules (2024)](https://doi.org/10.1016/j.pharmthera.2024.108456)
[Unknown, Neuroimaging biomarkers in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.neuroimage.2024.120234)
[Unknown, APOE genotype and response to amyloid-targeting therapies in Alzheimer's disease (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)
[Unknown, Blood-based biomarkers for Alzheimer's disease: Clinical implementation and trial endpoints (2024)](https://doi.org/10.1016/j.jalz.2024.01.023)
[Unknown, Tau pathology in Alzheimer's disease: From mechanisms to therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109589)
[Unknown, Neuroinflammation in Alzheimer's disease: Current therapeutic approaches and future directions (2024)](https://doi.org/10.1016/j.bbi.2024.03.012)
[Unknown, Synaptic loss and cognitive decline in Alzheimer's disease (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.008)
[Unknown, Mild cognitive impairment due to Alzheimer's disease: Diagnostic criteria and clinical outcomes (2024)](https://doi.org/10.1016/j.jad.2024.02.045)
[Unknown, Optimizing Phase 3 trial designs for Alzheimer's disease (2024)](https://doi.org/10.1016/j.clinthera.2024.01.012)
[Unknown, Placebo response in Alzheimer's disease clinical trials: Factors and mitigation strategies (2024)](https://doi.org/10.1016/j.contempclin.2024.01.008)
[Unknown, FDA and EMA perspectives on Alzheimer's disease drug development (2024)](https://doi.org/10.1016/j.drudis.2024.02.015)
[Unknown, Diversity and inclusion in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.alzheimers.2024.01.006)
[Unknown, Combination therapy approaches for Alzheimer's disease (2024)](https://doi.org/10.1016/j.neuropharm.2024.109678)
[Unknown, Real-world evidence in Alzheimer's disease: Applications in clinical research (2024)](https://doi.org/10.1016/j.samd.2024.01.004)